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+ NK1 + population in the liver from the transfectant-vacskin following the amputation of the tumor-bearing limb cinated mice. These results suggest that tumor vaccines improved survival when compared with the vaccination of genetically modified to secrete IL-12 continuously at a relairradiated parental cells (control). Cytotoxic activities tively low level preferentially augment local antitumor against parental M5076 were significantly stronger in the activity in the liver rather than systemic immune responses. hepatic lymphocytes from the mice vaccinated with the ILIntroduction Improvement in treatment strategies for cancer has resulted in a prolongation of survival time of patients with malignancies. However, minimal residual lesions have been a major problem in the surgical management of cancer. 1 In clinical situations, malignant tumors spontaneously metastasize to the other organs and surgical excision of a primary lesion diminishes 'concomitant immunity' of tumors. [2] [3] [4] [5] In normal mice, experimental metastasis is produced by i.v. injection of tumor cells, but spontaneous metastasis is thought to occur in association with immunosuppression induced during the tumorbearing state. 6, 7 Therefore, alternative experimental approaches for the development of new modalities for minimal residual tumors have been sought. Furthermore, by considering individual characteristics of various cancers, therapeutic modalities for a specific organ such as the liver, where metastasis frequently occurs, are of great importance.
Metastatic residual tumor is a potential target of gene therapy, ie a new antitumor modality, because conventional therapies are only palliative and metastatic cancers are usually fatal. 8 Meanwhile, most cytokines secreted by gene-transduced tumors express efficient antitumor Correspondence: N Fuji Received 4 November 1998; accepted 1 February 1999 activities including both specific and nonspecific immune responses and they successfully reduce the tumorigenicity of the modified cells. 9 When used as a vaccine, [10] [11] [12] these cells elicit an immune memory which effectively inhibits a subsequent challenge with the parental tumor. 13 Moreover, some researchers have demonstrated that vaccine treatment using a cytokine or cofactor genemodified tumor cells can present therapeutic effects against established tumors.
14,15 Nevertheless, no studies have examined therapeutic efficacy of gene-transduced tumor vaccines for spontaneous hepatic metastases.
IL-12 [16] [17] [18] [19] [20] augments proliferation and cytotoxic activity of T and NK cells, induces IFN-␥ production and facilitates T helper type 1 (Th1) response. In vivo administration of rIL-12 to mice not only induces specific CTL response, 21 but also results in reduction of experimental pulmonary and hepatic metastases of various tumors. 22 In addition, rIL-12 has been shown to induce NK1 + CD3 + (NKT) cells in the liver, which are potent cytotoxic effector cells against tumors. 23 Consequently, specific antitumor immunity is expected to be more vigorous not only by IL-12 delivery, but also by adding tumor-specific immunity using cytokine genetransduced tumor cells as a cellular vaccine.
In this study, we used a spontaneous liver metastases model of a murine tumor and an IL-12 gene-transduced tumor vaccine and investigated a new strategy which utilizes NKT cell-mediated antitumor effects of secreted IL-12 itself and which possesses preventive and therapeutic effects on tumors as a vaccine. In order to examine whether M5076/IL-12 cells possess therapeutic efficacy to residual minimal hepatic metastases, we conducted stepby-step experiments in the following order: (1) whether M5076/IL-12 cells themselves can reduce spontaneous hepatic metastases; (2) whether M5076/IL-12 cells admixed with M5076 cells can suppress the growth of the parental M5076 cells; and (3) whether M5076/IL-12 cells suppress hepatic metastasis of M5076 cells in mice whose primary lesion was surgically removed. We also examined the immunotherapeutic properties of an IL-12 genetransduced tumor vaccine against residual minimal hepatic metastases.
Results
Spontaneous hepatic metastasis model M5076 is the reticulum cell sarcoma and it non-immunogenically and preferentially metastasizes to the liver regardless of the site and route of tumor cell injection. 24, 25 Subcutaneous injection of 1 × 10 6 viable M5076 tumor cells to the footpad on day 0 induced spontaneous hepatic metastases in all mice on day 14 and all mice with or without amputation of the tumor-bearing limb (the primary tumor lesion) on day 14 died of liver metastases. Therefore, this model was used as a spontaneous liver metastasis model.
M5076/IL-12 cells inhibited spontaneous hepatic metastases
A preparatory study showed that in vitro tumorigenicity of IL-12 gene-transduced M5076 tumor was markedly weaker than M5076 (data not shown). Therefore, we started investigation on spontaneous metastasis of M5076 tumor. After the tumor injection, mice did or did not undergo amputation of the tumor-bearing limb on day 14 and all mice were killed on day 28 in order to examine their liver weight (Figure 1a) . Overall, the liver weight in the mice which received M5076/IL-12 cells (1.24 ± 0.03 g, mean ± s.e.) was significantly lower (P Ͻ 0.001) than that in the mice which received M5076 cells (2.19 ± 0.22 g). In the non-amputation mice, there were no significant differences between the mice with M5076 cells (1.84 ± 0.29 g) and mice with M5076/IL-12 cells (1.24 ± 0.04 g), whereas in the amputation groups, the liver weight in the mice with M5076 cells (2.55 ± 0.31 g) was significantly heavier (P = 0.002) than in mice with M5076/IL-12 cells (1.23 ± 0.04 g). The weight of the liver in age-and sexmatched normal mice was 1.16 ± 0.08 g.
The survival curves for animals which received 1 × 10 6 M5076 cells or 1 × 10 6 M5076/IL-12 cells followed by the amputation of the tumor-bearing limb on day 14, or for animals without amputation are shown in Figure 1b . All non-amputated mice which received parental M5076 tumor died of massive tumor in the liver before day 47. Interestingly, all amputated mice which received injection of parental tumor died before day 38 and their survival rate was significantly lower (P = 0.010) than that of non-amputated mice which also received M5076 tumor cells. In the groups which received injection of M5076/IL-12 cells, all of the 10 amputated mice and eight of the 10 non-amputated mice were alive on day 77. ) to the flank on day 0 (n = 10 each, Figure 2a ). On day 21, tumor diameters were significantly smaller in mice that received M5076 Figure 3 , all mice which received vaccinations of M5076 cells died of massive tumor in the liver before day 39, however, more than 13% of the mice (4/30) which received vaccinations of M5076/IL-12 cells (P = 0.004) were alive on day 80 and they were considered cured. The four cured mice were then challenged with a tumorigenic dose of parental M5076 tumor cells (1 × 10 4 cells per mouse) on the flank on day 100, and two of them effectively rejected the tumor. However, the cured mice were unable to reject other tumor cells of syngeneic mice, ie MC-38 which were injected in the same manner on day 100. These findings indicate that vaccination of transduced IL-12-producing tumor cells was efficacious in causing regression to residual hepatic tumor and in establishing a specific and long-lasting antitumor immunity against parental tumor.
Antitumor activities in vaccinated mice which bear hepatic metastases: differences of immune responses between spleen cells and hepatic lymphocytes Cytotoxicity: We examined whether immunological responses are different between the hepatic (metastasis) lesions and the systemic immunology in the early period of vaccination given to residual minimal metastasis. To assess whether vaccination activates CTL responses, spleen cells and hepatic lymphocytes of the mice which bear M5076, hepatic micrometastases were tested for the presence of antitumor CTL activity on POD 7 ( Figure 4 ). CTL activity in the spleen cells was 11.1 ± 2.0% in the mice vaccinated with M5076, and 10.6 ± 2.4% in the mice with M5076/IL-12 and there were no significant group differences. Whereas, in the M5076-vaccinated mice, cyto- toxicity generated from the hepatic lymphocytes was higher than that from the spleen cells. Moreover, there was a 1.5-fold increase of the cytotoxic activity of hepatic lymphocytes in the M5076/IL-12-treated mice (44.6 ± 8.0%) from the level in the M5076-treated mice (28.3 ± 6.6%, P = 0.012) (effector to target ratio, E/T = 80).
At the same time, we examined cytotoxicity against MC-38 tumor and the NK-sensitive tumor, YAC-1. The results showed cytotoxicity of spleen cells against MC-38 was 9.0 ± 2.3% in the M5076-treated mice and 10.4 ± 3.1% in the M5076/IL-2-treated mice and the cytotoxicity against YAC-1 was 12.5 ± 3.0% in the M5076-treated mice and 12.5 ± 3.0% in the M5076/IL-12-treated mice. There were no significant differences between the treatment groups. On the other hand, cytotoxic activity of hepatic lymphocytes against MC-38 was 10.3 ± 1.5% in the M5076-treated mice and 14.2 ± 1.9% in the M5076/IL-12-treated mice (E/T = 80), and cytotoxicity of hepatic lymphocytes against YAC-1 (NK activity) was significantly higher in the M5076/IL-12-treated mice (65.5 ± 8.8%) than in M5076-treated mice (38.0 ± 7.6%, P = 0.047) (E/T = 80). In other words, cytotoxicity of hepatic lymphocytes was the strongest against YAC-1, then against M5076, and the weakest against MC-38. This indicated that the effector cells (ie spleen cells and hepatic lymphocytes) in the early treatment period (POD 7) possess a certain degree of tumor-specificity, though it would be limited. Comparison between the M5076-treated and M5076/IL-12-treated mice showed that IL-12-secreting tumor vaccine augmented cytotoxicity of hepatic lymphocytes against the three targets more preferentially than that of spleen cells.
IFN-␥ production:
As shown in Figure 5 , IFN-␥ production in the spleen cells from the mice vaccinated with M5076 was 21.0 ± 1.8 pg/ml and that with M5076/IL-12 cells was 28.9 ± 2.2 pg/ml. However, hepatic lymphocytes from the M5076/IL-12-vaccinated mice released a twice higher level of IFN-␥ (155.9 ± 7.2 pg/ml) than the M5076-vaccinated mice (76.9 ± 13.2 pg/ml, P = 0.006). Interestingly, IFN-␥ and IL-12 levels were undetectable (Ͻ10 pg/ml) in serum samples from all mice (data not shown).
Immunophenotypes: In the above-mentioned experiments, significantly high therapeutic efficacy was observed in the M5076/IL-12-treated mice and hepatic lymphocytes presented a high cytotoxic activity. Therefore, in order to clarify the types of spleen cells and hepatic lymphocytes, which are involved in the cytotoxicity, we quantitatively analyzed phenotypic changes in these cells, ie ( 
CD8
+ cells decreased proportionally (22.5 ± 1.4% to 17.1 ± 1.1%) and CD4 + CD8 − cells were slightly augmented (33.4 ± 1.4% to 34.9 ± 2.0%) (Figure 6e and f) . This was also shown in a recent report using rIL-12 administration, 26 though in the present study, there were no significant differences. On the other hand, the proportion of CD3
+ cells in hepatic lymphocytes from the M5076/IL-12 group increased significantly (25.9 ± 1.2%) when compared with the M5076 group (16.8 ± 2.1%, P = 0.042) (Figure 6g and h). Because we did not find significant changes in the CD4-positive/negative CD8-negative/positive cells, the effector cells in the early treatment period of IL-12-secreting tumor vaccine would not be CD8 + T cells, while NKT cells are expected to be involved in efficacy in the early treatment period.
Discussion
Systemic administration of rIL-12 is reported to reduce experimental pulmonary and hepatic metastases of murine tumors 22 and cytokine gene-transduced tumor cell vaccines eradicated micrometastases. 10,27-29 However, it is still unclear whether these vaccines actually have antitumor effects on spontaneously metastasized tumors which are often encountered in clinical cases. The first experiments in the present study demonstrated that (1) transfectant of M5076 reticulum cell sarcoma with IL-12 gene could practically prevent spontaneous hepatic metastases; and (2) IL-12 gene-transduced M5076 cells, which are inoculated with parental M5076 tumor cells, could reduce tumorigenicity and suppress spontaneous liver metastases of the parental tumor. Based on these findings, we examined vaccination properties of IL-12 genetransduced tumor cells against residual hepatic micrometastases after surgical resection of the primary tumor, ie amputation of the tumor-bearing limb. Consequently, vaccination resulted in a significant prolongation of survival time of mice with hepatic metastases and four of the 30 mice were considered cured. These results revealed that local and continuous release of IL-12 using genetically modified tumor vaccines, as well as rIL-12 administration, could generate therapeutic effects against residual hepatic tumors.
With regard to therapeutic efficacy of IL-12-secreting tumor vaccines against hepatic micrometastases, we investigated the immune activities of hepatic lymphocytes as a local effector of tumor-bearing livers and spleen cells as a parameter of systemic immune responses. The 51 Cr release cytotoxicity assay revealed that percentage cytolysis in the hepatic lymphocytes from the M5076/IL-12-vaccinated mice increased significantly from the level in the M5076-vaccinated mice, while there were no differences between the spleen cells from the M5076/IL-12-or M5076-vaccinated mice (Figure 4) . We consider that high cytotoxicity found on hepatic lymphocytes even without conducting mixed lymphocyte tumor culture (MLTC) was very important, because this finding shows that the effector cells would possess a high in vivo cytotoxic activity. IFN-␥ production could be a more reliable predictor for therapeutic efficacy than CTL activity. 13, 30 In the present study, IFN-␥ in the spleen cells from the M5076/IL-12-treated mice increased slightly when compared with the M5076-treated mice ( Figure 5 ). Nevertheless, hepatic lymphocytes from the M5076/IL-12-vaccinated mice produced a two-fold or higher level of IFN-␥ than those from the M5076-vaccinated mice ( Figure 5 ), even though cytotoxicity assay showed that cytolytic activity of the former group was only 1.5-fold higher at most, than the latter group (Figure 4) . Unexpectedly, both cytotoxic activity and IFN-␥ production in spleen cells from the M5076/IL-12-vaccinated mice in the present study were low. This might be attributable to the lower IL-12 secretion in our model than in a previously reported rIL-12 administration regimen 22 and this would also be related to no MLTC in the present study. However, when we consider dose-dependent toxicity of IL-12, 21, 31, 32 it is quite important that actual therapeutic antitumor effects were observed at a relatively low, local IL-12 secretion by using genetically engineered tumor cells. As a result of the present treatment, immune responses enhanced by IL-12 gene-transduced tumor vaccines were much stronger in hepatic lymphocytes than in spleen cells. In other words, continuous and low IL-12 secretion using these tumor vaccines could enhance local antitumor activities in the liver rather than in the systemic immune response.
Figure 6 Phenotypic analysis of spleen cells and hepatic lymphocytes obtained on POD 7 from the mice with M5076 or M5076/IL-12 vaccinations. The cells were stained with FITC-conjugated anti-CD4 and PE-conjugated anti-CD8 Abs (a, b, e, f), or with FITC-conjugated anti-CD3 and PEconjugated anti-NK1.1 Abs (c, d, g, h). Percentage of CD3
The main reason why IL-12-producing tumor vaccines are therapeutically effective against hepatic metastases is suggested to be the markedly higher proportion of NKT cells in hepatic lymphocytes than in spleen cells. 23 In fact, our findings in the fluorescence-activated cell sorter analysis (FACS, Figure 6 ) were similar to those in a recent report using rIL-12 administration. 26 Presence of abundant NKT cells in the liver is also supported by a recent study which demonstrated IL-12-mediated tumor rejection requires V ␣ 14 NKT cells. 33 36 As another mechanism of therapeutic efficacy of IL-12-secreting tumor vaccines, not only NKT cells, but T cells and/or NK cells may also participate in the reduction of hepatic micrometastases. Moreover, in the present study, 50% of mice that survived (Figure 3 ) which received a rechallenge of the parental tumor, rejected the tumor and this clearly demonstrated that the essential property of tumor vaccine is the generation of tumorspecific immunological memory. Thus, immunotherapy using IL-12-altered tumor vaccine would be a useful therapeutic modality for minimal residual hepatic tumors, because in the early treatment stage, this strategy confers an efficient immune response, ie increase of NKT cells which possess potent antitumor activities in the tumor-bearing liver and in the later stage, this strategy could result in the acquisition of long-lasting immunity in which T cells could be involved.
After the removal of a growing primary tumor, concomitant immunity is frequently deteriorated and spontaneous metastases are facilitated as already shown by other investigators using different models 3-5 and as shown in Figure 1 . Therefore, the possible complement of the concomitant immunity by IL-12-secreting vaccine cells and the antitumor effects of the vaccines against minimal residual tumors are quite important.
The s.c. vaccination using IL-12 gene-transduced tumor cells is a relatively simple modality in comparison to the infusion of these cells into appropriate vessels, eg hepatic artery or portal vein. On the other hand, a problem in gene transfer in vivo is a low gene delivery rate when retroviral vectors are used, 37 and a high immunogenicity when adenoviral vectors are used. 38, 39 In the present study, our vaccination induced effective antitumor immunity, but the efficacy was marginal in respect of the cure of the animals which had postoperative micrometastases (Figure 3) . In order to develop better vaccination strategies, we should investigate such critical parameters as cytokines used in the treatment, cytokine expression levels, vaccination dosage, site of immunization and vaccination schedule. 10 Our findings implicated that IL-12 could be usable for tumors which preferentially metastasize to the liver, without diminishing concomitant immunity. However, IL-12 is not always good for other tumors which metastasize to other organs. IL-12-secreting vaccine cells might also be effective against pulmonary residual tumors, because a recent study showed that IL-12 induced a significant number of NKT cells with cytotoxicity at a similar potency in the lung. 34 Moreover, IL-12 induces IFN-␥, and IFN-␥-inducible protein 10 (IP-10) mediated by the IFN-␥ production is recently reported to strongly inhibit angiogenesis during tumorigenesis. 40, 41 Therefore, IP-10 may take a role in antitumor activity of IL-12 in vivo. The latest study showed that tumor therapy based on IL-12 gene transduction was effective on a MHC-negative murine metastatic melanoma 42 and suggested applicability of this gene therapy to MHC-defective human neoplasms. Further investigations in regard to cancer remedies which utilize characteristics of specific cancer should be conducted. We hope the present study will provide a basis for future investigations which will refine the usage of cancer vaccines to prevent and treat postoperative residual tumors.
Materials and methods

Tumor and mice
The reticulum cell sarcoma M5076 arose as a spontaneous tumor in the ovary of a C57BL/6 female mouse. 24 The tumor cells were isolated from ascites-passaged tumors and cultured in RPMI 1640 medium supplemented with 17% heat-inactivated equine serum, 100 IU/ml penicillin, 100 g/ml streptomycin, and 50 m of 2-mercaptoethanol in humidified air containing 5% CO 2 at 37°C. M5076 tumor cells express either class I or class II MHC gene products at quite a low level and the addition of IFN-␥ to the culture did not enhance MHC class I expression (data not shown).
Female C57BL/6 mice (Japan SLC, Hamamatsu, Japan) were treated according to the approved guidelines of Kyoto Prefectural University of Medicine and used in experiments at between 8 and 12 weeks of age.
IL-12 gene transduction IL-12-secreting M5076 cells were produced by transduction with the retroviral vector TFG-mIL-12-Neo. 43 This vector encodes p40 and p35 murine IL-12 subunits as well as the neomycin phosphotransferase gene and it was generously provided by Dr H Tahara (University of Pittsburgh, Pittsburgh, PA, USA). M5076 cells were infected with retroviral supernatant on fibronectin-coated plates (Sumitomo Bakelite, Tokyo, Japan) and after one passage, infected cells were selected in complete medium with G418 at a concentration of 0.6 mg/ml. G418-resistant colonies were collected and expanded to determine their IL-12 production measured by a bioassay using human phytohemagglutinin-activated lymphoblasts 44 and a specific ELISA (Genzyme, Cambridge, MA, USA). In vitro growth rate of IL-12 gene-transduced cells did not differ from that of the parental cells and no modifications due to gene transduction were found on such membrane molecules as MHC class I, class II and the costimulatory factor B7 (data not shown). However, in vivo tumorigenicity of IL-12 genetransduced M5076 cells was diminished along with the increase of IL-12 production level (data not shown). The best colony which produces 41 ng mIL-12/10 6 cells/48 h was used in this study (M5076/IL-12 cells). ) were injected into the flank of the mice (n = 10 each) on day 0 and tumor growth at the injection site was investigated. In another 40 mice, the same admixture was injected on the footpad on day 0, the tumor-bearing limb was amputated on day 14 and their survival time was monitored.
Spontaneous hepatic metastasis model
Each experiment was performed at least three times and the results of a representative experiment are presented.
Vaccination treatment with M5076 cells engineered to release IL-12
Residual hepatic metastasis model for vaccination: To establish a model of residual hepatic micrometastases which mimic clinical situations, mice received s.c. injection of 1 × 10 6 viable M5076 cells to the footpad on day 0 and their tumor-bearing limbs were amputated on day 14. Based on the confirmation made on the spontaneous hepatic metastasis model, all mice are thought to have had liver metastases at that time. Then, immunotherapy using s.c. vaccination of irradiated (25 Gy) 1 × 10 6 M5076 cells (control) or irradiated M5076/IL-12 cells to the flank was administered on POD 0 and 3.
Preparation of spleen cells and hepatic lymphocytes: For in vitro experiments to evaluate the immunotherapeutic properties, spleen cells and hepatic lymphocytes were obtained on POD 7 from the vaccine-treated mice. Under deep ether anesthesia, the axillary artery was cut and the blood was extracted, and the spleen and liver were aseptically extracted. Spleen cells were prepared by forcing the spleen through a 150-gauge stainless steel mesh followed by treating with RBC lysis solution (0.15 m NH 4 Cl, 0.1 mm EDTA, 10 mm KHCO 3 ). Hepatic lymphocytes were isolated by density gradient centrifugation using a modification of previously described procedures. 26, 45 Briefly, the liver was passed through a mesh and suspended in RPMI 1640. After washing, the pellet was resuspended in RBC lysis solution and washed again.
The cell suspension was overlaid on Lympholyte-M (1.088) (Cedarlane, Hornby, Canada) and centrifuged at 350 g for 20 min at room temperature. The interface was aspirated, washed twice and subjected to in vitro assays.
Cytotoxicity assay: The target cells, M5076, were labeled with 100 Ci (per 2 × 10 6 cells) of Na 2
51
CrO 4 for 60 min at 37°C in complete medium and washed twice with the medium. Labeled targets (5 × 10 3 cells per well) were incubated in a total volume of 200 l with effector cells in 10% fetal calf serum (FCS)-RPMI 1640 in 96-well roundbottom microtiter plates. The plates were centrifuged before incubation and after 16 h of incubation, the supernatant was harvested and counted in a ␥ counter. Cytotoxicity was calculated as the percentage of releasable counts after subtraction of the spontaneous release.
IFN-␥ production: Spleen cells and hepatic lymphocytes were obtained from the vaccine-treated mice on POD 7. These cells were suspended in RPMI 1640 medium with 10% FCS at a density of 5 × 10 6 cells/ml, and irradiated (25 Gy) M5076 cells were suspended in the medium at a density of 2 × 10 5 cells/ml. Then 1 ml of each was poured on to 24-well plates (total 2 ml) to stimulate the spleen cells and hepatic lymphocytes with the irradiated M5076 cells. Supernatants harvested after 48-h incubation in a humidified atmosphere of 5% CO 2 in air at 37°C were tested in a specific ELISA for IFN-␥ (Genzyme). At the same time, IFN-␥ and IL-12 in the serum were measured by using specific ELISA.
Immunophenotypic analysis: Surface phenotypes of the cells were identified by using mAbs in conjunction with a two-color immunofluorescence test. The mAbs used included FITC anti-mouse CD3 (145-2C11), FITC antimouse CD4 (RM4-4), PE anti-mouse CD8 (53-6.7), and PE anti-mouse NK1.1 (PK136), all of which were purchased from PharMingen (San Diego, CA, USA). The presence of fluorescence-positive cells was analyzed by FACS Calibur (Becton Dickinson, Mountain View, CA, USA).
Statistical analysis
Animals' survival time was compared with the KaplanMeier estimates and the significance was determined by the generalized Wilcoxon test. A paired Student's t test was used to compare mean percentage of fluorescence channel numbers for gated populations of cells analyzed by flow cytometry, and mean percentage of cytolysis in 51 Cr release assay. In these cases, paired samples from different mice were stained in parallel and analyzed sequentially using the same flow cytometer parameter settings and they were incubated simultaneously using the same procedure. Analysis of variance (ANOVA) and Student's t test were used to analyze the other data. The results are shown as mean ± s.e. The differences were considered statistically significant when the P value was less than 0.05.
